DE10220230A1 - Verwendung von Rotigotine zur Behandlung des Restless Leg Syndroms - Google Patents
Verwendung von Rotigotine zur Behandlung des Restless Leg SyndromsInfo
- Publication number
- DE10220230A1 DE10220230A1 DE10220230A DE10220230A DE10220230A1 DE 10220230 A1 DE10220230 A1 DE 10220230A1 DE 10220230 A DE10220230 A DE 10220230A DE 10220230 A DE10220230 A DE 10220230A DE 10220230 A1 DE10220230 A1 DE 10220230A1
- Authority
- DE
- Germany
- Prior art keywords
- acrylate
- tetrahydro
- thienyl
- ethyl
- propyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 208000005793 Restless legs syndrome Diseases 0.000 title claims abstract description 56
- 229960003179 rotigotine Drugs 0.000 title claims description 22
- KFQYTPMOWPVWEJ-INIZCTEOSA-N rotigotine Chemical compound CCCN([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 KFQYTPMOWPVWEJ-INIZCTEOSA-N 0.000 title claims description 22
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 36
- 238000011282 treatment Methods 0.000 claims abstract description 23
- 229920001296 polysiloxane Polymers 0.000 claims abstract description 21
- 239000000902 placebo Substances 0.000 claims abstract description 13
- 229940068196 placebo Drugs 0.000 claims abstract description 13
- 230000006872 improvement Effects 0.000 claims abstract description 12
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 40
- 239000000853 adhesive Substances 0.000 claims description 32
- 239000011159 matrix material Substances 0.000 claims description 30
- 230000001070 adhesive effect Effects 0.000 claims description 29
- RPQRDASANLAFCM-UHFFFAOYSA-N oxiran-2-ylmethyl prop-2-enoate Chemical compound C=CC(=O)OCC1CO1 RPQRDASANLAFCM-UHFFFAOYSA-N 0.000 claims description 26
- 239000003814 drug Substances 0.000 claims description 17
- 229940100640 transdermal system Drugs 0.000 claims description 17
- KFQYTPMOWPVWEJ-UHFFFAOYSA-N 6-{propyl[2-(thiophen-2-yl)ethyl]amino}-5,6,7,8-tetrahydronaphthalen-1-ol Chemical compound C1CC2=C(O)C=CC=C2CC1N(CCC)CCC1=CC=CS1 KFQYTPMOWPVWEJ-UHFFFAOYSA-N 0.000 claims description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 14
- 239000000126 substance Substances 0.000 claims description 14
- 239000004480 active ingredient Substances 0.000 claims description 13
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 13
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 13
- 150000001875 compounds Chemical class 0.000 claims description 12
- 229920000642 polymer Polymers 0.000 claims description 12
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 11
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 11
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 10
- 239000013464 silicone adhesive Substances 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 8
- 239000012458 free base Substances 0.000 claims description 8
- 150000001412 amines Chemical class 0.000 claims description 7
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 7
- 239000000194 fatty acid Substances 0.000 claims description 7
- 229930195729 fatty acid Natural products 0.000 claims description 7
- -1 hexyl methyl Chemical group 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 7
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 claims description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims description 6
- 229920001577 copolymer Polymers 0.000 claims description 6
- 235000011187 glycerol Nutrition 0.000 claims description 6
- 229910052909 inorganic silicate Inorganic materials 0.000 claims description 6
- 239000000725 suspension Substances 0.000 claims description 6
- 239000002585 base Substances 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- CEXBONHIOKGWNU-NTISSMGPSA-N hydron;(6s)-6-[propyl(2-thiophen-2-ylethyl)amino]-5,6,7,8-tetrahydronaphthalen-1-ol;chloride Chemical compound [Cl-].CCC[NH+]([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 CEXBONHIOKGWNU-NTISSMGPSA-N 0.000 claims description 5
- 230000001681 protective effect Effects 0.000 claims description 5
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- 150000004665 fatty acids Chemical class 0.000 claims description 4
- 229920001477 hydrophilic polymer Polymers 0.000 claims description 4
- 229940055577 oleyl alcohol Drugs 0.000 claims description 4
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 150000003505 terpenes Chemical class 0.000 claims description 4
- 235000007586 terpenes Nutrition 0.000 claims description 4
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 3
- 239000005977 Ethylene Substances 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 229920001451 polypropylene glycol Polymers 0.000 claims description 3
- 235000019795 sodium metasilicate Nutrition 0.000 claims description 3
- 229910052911 sodium silicate Inorganic materials 0.000 claims description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 2
- GOXQRTZXKQZDDN-UHFFFAOYSA-N 2-Ethylhexyl acrylate Chemical compound CCCCC(CC)COC(=O)C=C GOXQRTZXKQZDDN-UHFFFAOYSA-N 0.000 claims description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 2
- WDQMWEYDKDCEHT-UHFFFAOYSA-N 2-ethylhexyl 2-methylprop-2-enoate Chemical compound CCCCC(CC)COC(=O)C(C)=C WDQMWEYDKDCEHT-UHFFFAOYSA-N 0.000 claims description 2
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 claims description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 claims description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical class CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 2
- 239000005642 Oleic acid Substances 0.000 claims description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- CQEYYJKEWSMYFG-UHFFFAOYSA-N butyl acrylate Chemical compound CCCCOC(=O)C=C CQEYYJKEWSMYFG-UHFFFAOYSA-N 0.000 claims description 2
- BLCTWBJQROOONQ-UHFFFAOYSA-N ethenyl prop-2-enoate Chemical compound C=COC(=O)C=C BLCTWBJQROOONQ-UHFFFAOYSA-N 0.000 claims description 2
- 150000002191 fatty alcohols Chemical class 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 150000002314 glycerols Chemical class 0.000 claims description 2
- LNMQRPPRQDGUDR-UHFFFAOYSA-N hexyl prop-2-enoate Chemical compound CCCCCCOC(=O)C=C LNMQRPPRQDGUDR-UHFFFAOYSA-N 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 2
- FQPSGWSUVKBHSU-UHFFFAOYSA-N methacrylamide Chemical compound CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 239000000178 monomer Substances 0.000 claims description 2
- NZIDBRBFGPQCRY-UHFFFAOYSA-N octyl 2-methylprop-2-enoate Chemical compound CCCCCCCCOC(=O)C(C)=C NZIDBRBFGPQCRY-UHFFFAOYSA-N 0.000 claims description 2
- 229940065472 octyl acrylate Drugs 0.000 claims description 2
- ANISOHQJBAQUQP-UHFFFAOYSA-N octyl prop-2-enoate Chemical compound CCCCCCCCOC(=O)C=C ANISOHQJBAQUQP-UHFFFAOYSA-N 0.000 claims description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 2
- 229910052913 potassium silicate Inorganic materials 0.000 claims description 2
- 235000019353 potassium silicate Nutrition 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 4
- 239000000243 solution Substances 0.000 description 18
- 230000000694 effects Effects 0.000 description 15
- 238000002560 therapeutic procedure Methods 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 8
- 238000009097 single-agent therapy Methods 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 5
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 5
- 239000011505 plaster Substances 0.000 description 5
- 229920006267 polyester film Polymers 0.000 description 5
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 4
- 206010038743 Restlessness Diseases 0.000 description 4
- 229940052760 dopamine agonists Drugs 0.000 description 4
- 229960004502 levodopa Drugs 0.000 description 4
- 229920000058 polyacrylate Polymers 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 229960002896 clonidine Drugs 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 208000019116 sleep disease Diseases 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 2
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 229920003149 Eudragit® E 100 Polymers 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 229920003082 Povidone K 90 Polymers 0.000 description 2
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000003416 augmentation Effects 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- 150000001557 benzodiazepines Chemical class 0.000 description 2
- NEDGUIRITORSKL-UHFFFAOYSA-N butyl 2-methylprop-2-enoate;2-(dimethylamino)ethyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.CCCCOC(=O)C(C)=C.CN(C)CCOC(=O)C(C)=C NEDGUIRITORSKL-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 239000002050 international nonproprietary name Substances 0.000 description 2
- 238000011294 monotherapeutic Methods 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 229940127240 opiate Drugs 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 208000035824 paresthesia Diseases 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 229960003089 pramipexole Drugs 0.000 description 2
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000003867 tiredness Effects 0.000 description 2
- 208000016255 tiredness Diseases 0.000 description 2
- 229960000984 tocofersolan Drugs 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 206010040981 Sleep attacks Diseases 0.000 description 1
- 239000004115 Sodium Silicate Substances 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 239000002313 adhesive film Substances 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 125000003289 ascorbyl group Chemical group [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- 229960004596 cabergoline Drugs 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- ZJQPLBFKBQYYIO-UHFFFAOYSA-N dodecasodium;trisilicate Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-] ZJQPLBFKBQYYIO-UHFFFAOYSA-N 0.000 description 1
- 239000000534 dopa decarboxylase inhibitor Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007970 homogeneous dispersion Substances 0.000 description 1
- CEXBONHIOKGWNU-UHFFFAOYSA-N hydron;6-[propyl(2-thiophen-2-ylethyl)amino]-5,6,7,8-tetrahydronaphthalen-1-ol;chloride Chemical compound Cl.C1CC2=C(O)C=CC=C2CC1N(CCC)CCC1=CC=CS1 CEXBONHIOKGWNU-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 208000036260 idiopathic disease Diseases 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960003587 lisuride Drugs 0.000 description 1
- 238000012153 long-term therapy Methods 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000003547 miosis Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- IHYNKGRWCDKNEG-UHFFFAOYSA-N n-(4-bromophenyl)-2,6-dihydroxybenzamide Chemical compound OC1=CC=CC(O)=C1C(=O)NC1=CC=C(Br)C=C1 IHYNKGRWCDKNEG-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940071462 oralone Drugs 0.000 description 1
- 229960004851 pergolide Drugs 0.000 description 1
- YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 229960001879 ropinirole Drugs 0.000 description 1
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 238000012154 short term therapy Methods 0.000 description 1
- 229920002050 silicone resin Polymers 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 230000004620 sleep latency Effects 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical compound [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- XJSMBWUHHJFJFV-VTIMJTGVSA-N α-dihydroergocryptine Chemical compound C([C@H]1N(C)C2)C([C]34)=CN=C4C=CC=C3[C@H]1C[C@H]2C(=O)N[C@@]1(C(C)C)C(=O)N2[C@@H](CC(C)C)C(=O)N3CCC[C@H]3[C@]2(O)O1 XJSMBWUHHJFJFV-VTIMJTGVSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (30)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10220230A DE10220230A1 (de) | 2002-05-06 | 2002-05-06 | Verwendung von Rotigotine zur Behandlung des Restless Leg Syndroms |
| US10/429,283 US20040048779A1 (en) | 2002-05-06 | 2003-05-02 | Use of rotigotine for treating the restless leg syndrome |
| RU2004131866/15A RU2301063C9 (ru) | 2002-05-06 | 2003-05-05 | Форма для трансэпикутанного введения для лечения синдрома усталых ног |
| PL373276A PL218549B1 (pl) | 2002-05-06 | 2003-05-05 | Zastosowanie rotygotyny do wytwarzania leku do przezskórnego leczenia Zespołu Niespokojnych Nóg |
| AT03727432T ATE387912T1 (de) | 2002-05-06 | 2003-05-05 | Transepikutane darreichungsform zur behandlung des restless leg syndroms |
| EP03727432A EP1501499B1 (de) | 2002-05-06 | 2003-05-05 | Transepikutane darreichungsform zur behandlung des restless leg syndroms |
| ES03727432T ES2301795T3 (es) | 2002-05-06 | 2003-05-05 | Forma de administracion transepicutanea para el tratamiento del sindrome de las piernas inquietas. |
| MXPA04010687A MXPA04010687A (es) | 2002-05-06 | 2003-05-05 | Forma de administracion transepicutanea para tratar sindrome de pierna temblorosa. |
| DK03727432T DK1501499T3 (da) | 2002-05-06 | 2003-05-05 | Transepikutan indgivelsesform til behandling af restless legs-syndromet |
| CA2787384A CA2787384A1 (en) | 2002-05-06 | 2003-05-05 | Polymeric adhesive transdermal patch comprising rotigotine for treatment of restless leg syndrome |
| CA2483120A CA2483120C (en) | 2002-05-06 | 2003-05-05 | Polymeric adhesive transdermal patch comprising rotigotine for treatment of restless leg syndrome |
| PCT/EP2003/004685 WO2003092677A1 (de) | 2002-05-06 | 2003-05-05 | Transepikutane darreichungsform zur behandlung des restless leg syndroms |
| UA20041109078A UA81625C2 (ru) | 2002-05-06 | 2003-05-05 | Применение ротиготина для трансепикутального лечения синдрома уставших ног |
| BR0309837-0A BR0309837A (pt) | 2002-05-06 | 2003-05-05 | Forma de administração trans-epicutânea para tratamento da sìndrome das pernas inquietas |
| HK05105199.3A HK1072541B (en) | 2002-05-06 | 2003-05-05 | Trans-epicutaneous administration form for treating restless leg syndrome |
| SI200331195T SI1501499T1 (sl) | 2002-05-06 | 2003-05-05 | Oblika za transepikutano dajanje za zdravljenje sindroma nemirnih nog |
| DE50309318T DE50309318D1 (de) | 2002-05-06 | 2003-05-05 | Transepikutane darreichungsform zur behandlung des restless leg syndroms |
| JP2004500861A JP5253707B2 (ja) | 2002-05-06 | 2003-05-05 | レストレスレッグス症候群を処置するための経外角皮的投与形 |
| AU2003233233A AU2003233233B2 (en) | 2002-05-06 | 2003-05-05 | Trans-epicutaneous administration form for treating restless leg syndrome |
| PT03727432T PT1501499E (pt) | 2002-05-06 | 2003-05-05 | Forma de administração trans-epicutânea para tratamento da síndroma das pernas inquietas |
| CNB038160250A CN100396281C (zh) | 2002-05-06 | 2003-05-05 | 治疗不宁腿综合症的经皮给药方式 |
| NZ536533A NZ536533A (en) | 2002-05-06 | 2003-05-05 | Trans-epicutaneous administration form for treating restless leg syndrome |
| IL16486103A IL164861A0 (en) | 2002-05-06 | 2003-05-05 | Trans-epicutaneous administration form for treating restless leg syndrome |
| KR10-2004-7017685A KR20040104697A (ko) | 2002-05-06 | 2003-05-05 | 하지불안증후군 치료용 경피투여 형태 |
| IL164861A IL164861A (en) | 2002-05-06 | 2004-10-27 | Use of rotigotine for the production of a medicament for treating restless leg syndrome |
| ZA2004/08862A ZA200408862B (en) | 2002-05-06 | 2004-11-02 | Trans epicutaneous administration form for treating restless leg syndrome |
| NO20045240A NO333619B1 (no) | 2002-05-06 | 2004-11-30 | Transepikutan administrasjonsform for a behandle restless leg syndromet |
| CY20081100471T CY1107452T1 (el) | 2002-05-06 | 2008-05-02 | Διαδερμικη μορφη χορηγησης για τη θεραπεια του συνδρομου ανησυχων ποδιων |
| JP2010098924A JP2010159302A (ja) | 2002-05-06 | 2010-04-22 | レストレスレッグス症候群を処置するための経外角皮的投与形 |
| US15/428,614 US20170151215A1 (en) | 2002-05-06 | 2017-02-09 | Use of rotigotine for treating the restless leg syndrome |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10220230A DE10220230A1 (de) | 2002-05-06 | 2002-05-06 | Verwendung von Rotigotine zur Behandlung des Restless Leg Syndroms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE10220230A1 true DE10220230A1 (de) | 2003-11-27 |
Family
ID=29285132
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE10220230A Ceased DE10220230A1 (de) | 2002-05-06 | 2002-05-06 | Verwendung von Rotigotine zur Behandlung des Restless Leg Syndroms |
| DE50309318T Expired - Lifetime DE50309318D1 (de) | 2002-05-06 | 2003-05-05 | Transepikutane darreichungsform zur behandlung des restless leg syndroms |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE50309318T Expired - Lifetime DE50309318D1 (de) | 2002-05-06 | 2003-05-05 | Transepikutane darreichungsform zur behandlung des restless leg syndroms |
Country Status (23)
| Country | Link |
|---|---|
| EP (1) | EP1501499B1 (https=) |
| JP (2) | JP5253707B2 (https=) |
| KR (1) | KR20040104697A (https=) |
| CN (1) | CN100396281C (https=) |
| AT (1) | ATE387912T1 (https=) |
| AU (1) | AU2003233233B2 (https=) |
| BR (1) | BR0309837A (https=) |
| CA (2) | CA2483120C (https=) |
| CY (1) | CY1107452T1 (https=) |
| DE (2) | DE10220230A1 (https=) |
| DK (1) | DK1501499T3 (https=) |
| ES (1) | ES2301795T3 (https=) |
| IL (2) | IL164861A0 (https=) |
| MX (1) | MXPA04010687A (https=) |
| NO (1) | NO333619B1 (https=) |
| NZ (1) | NZ536533A (https=) |
| PL (1) | PL218549B1 (https=) |
| PT (1) | PT1501499E (https=) |
| RU (1) | RU2301063C9 (https=) |
| SI (1) | SI1501499T1 (https=) |
| UA (1) | UA81625C2 (https=) |
| WO (1) | WO2003092677A1 (https=) |
| ZA (1) | ZA200408862B (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10041478A1 (de) | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung |
| DE10359528A1 (de) | 2003-12-18 | 2005-07-28 | Schwarz Pharma Ag | (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum |
| MY149152A (en) | 2006-05-08 | 2013-07-15 | Teikoku Seiyaku Kk | Percutaneous absorption preparations of antimentia drugs |
| TWI392670B (zh) | 2006-06-22 | 2013-04-11 | Ucb Pharma Gmbh | 經取代的２-胺基萘滿之於製造用於預防、減緩及／或治療各種類型疼痛之藥物上的用途 |
| EP1987815A1 (en) * | 2007-05-04 | 2008-11-05 | Schwarz Pharma Ag | Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders |
| NZ584363A (en) | 2007-11-28 | 2012-11-30 | Ucb Pharma Gmbh | Drug formulations of Rotigotine which comprise the thermodynamically stable polymorphic form 2 |
| US9155725B2 (en) | 2008-02-27 | 2015-10-13 | Hisamitsu Pharmaceutical Co., Inc. | Adhesive skin patch and packaged product |
| EP2255809B1 (en) * | 2008-02-27 | 2017-08-23 | Hisamitsu Pharmaceutical Co., Inc. | Medicated patch |
| EP2201941A1 (de) | 2008-12-29 | 2010-06-30 | UCB Pharma GmbH | Pflaster-Herstellungstechnologie |
| EP2281559A1 (en) | 2009-06-26 | 2011-02-09 | UCB Pharma GmbH | Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis |
| LT3257504T (lt) | 2009-12-22 | 2024-08-26 | UCB Biopharma SRL | Polivinilpirolidonas, skirtas nekristalinės formos kietos rotigotino dispersijos stabilizavimui |
| US8729306B2 (en) | 2010-02-05 | 2014-05-20 | Ucb Pharma Gmbh | Process for the preparation of nitrogen substituted aminotetralins derivatives |
| BR112012029944A2 (pt) | 2010-06-25 | 2019-09-24 | Ucb Pharma Gmbh | processo para preparação de derivados de aminotetralinas substituídas com nitrogênio |
| EP2559435A1 (en) | 2011-08-19 | 2013-02-20 | UCB Pharma GmbH | Rotigotine in the treatment of hemispatial neglect, stroke and deficits following stroke |
| WO2013075823A1 (en) | 2011-11-22 | 2013-05-30 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Transdermal therapeutic system comprising rotigotine and crystallization inhibitor |
| DE102012013439A1 (de) | 2012-07-03 | 2014-01-23 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Transdermales therapeutisches System umfassend Rotigotin und Kristallisationsinhibitor |
| DE102012013421A1 (de) | 2012-07-03 | 2014-01-09 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Transdermales therapeutisches System (TTS) mit Rotigotin |
| MX2015000049A (es) * | 2012-07-05 | 2015-04-08 | Sk Chemicals Co Ltd | Preparacion absorbible transdermicamente que contiene rotigotina. |
| EP2870963A4 (en) * | 2012-07-06 | 2016-03-09 | Sk Chemicals Co Ltd | PREPARATION CONTAINING ROTIGOTINE FOR PERCUTANEOUS ABSORBING |
| TW201431570A (zh) | 2012-11-22 | 2014-08-16 | Ucb Pharma Gmbh | 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片 |
| JP6726096B2 (ja) | 2013-07-03 | 2020-07-22 | エルテーエス ローマン テラピー−システメ アーゲー | 電子部品を有する経皮治療システム |
| WO2015129527A1 (ja) | 2014-02-27 | 2015-09-03 | 株式会社メドレックス | プラミペキソールを含有する神経変性疾患の治療用貼付剤 |
| CA2948219C (en) | 2014-05-20 | 2023-04-04 | Lts Lohmann Therapie-Systeme Ag | Method for adjusting the release of active agent in a transdermal delivery system |
| CN106456566B (zh) | 2014-05-20 | 2020-06-16 | Lts勒曼治疗系统股份公司 | 含罗替戈汀的经皮递送系统 |
| US11752110B2 (en) | 2014-05-20 | 2023-09-12 | Lts Lohmann Therapie-Systeme Ag | Transdermal delivery system including an interface mediator |
| JP6872675B1 (ja) | 2019-06-14 | 2021-05-19 | 久光製薬株式会社 | ロチゴチン含有貼付剤 |
| ES2966170T3 (es) | 2020-01-24 | 2024-04-18 | Luye Pharma Switzerland Ag | Sistema terapéutico transdérmico que comprende rotigotina y al menos un adhesivo de silicona no resistente a las aminas |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998031362A1 (en) * | 1997-01-17 | 1998-07-23 | Pharmacia & Upjohn Company | Use of pramipexole in the treatment of restless legs syndrome |
| DE19938825A1 (de) * | 1999-08-19 | 2001-04-26 | Boehringer Ingelheim Pharma | Wirkstoffkombination mit Clonidin |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5656286A (en) * | 1988-03-04 | 1997-08-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
| US5474783A (en) * | 1988-03-04 | 1995-12-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
| US5232702A (en) * | 1991-07-22 | 1993-08-03 | Dow Corning Corporation | Silicone pressure sensitive adhesive compositons for transdermal drug delivery devices and related medical devices |
| DE4238223C1 (de) * | 1992-11-12 | 1994-05-26 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System zur Verabreichung von Physostigmin an die Haut und Verfahren zu dessen Herstellung |
| US5482988A (en) * | 1994-01-14 | 1996-01-09 | Dow Corning Corporation | Hot-melt silicone pressure sensitive adhesive with siloxylated polyether waxes as additives |
| IL116539A (en) * | 1995-01-06 | 2002-02-10 | Noven Pharma | Preparations given through the skin of unstable anti-acid drugs |
| FR2749514B1 (fr) * | 1996-06-11 | 1998-08-07 | Hoechst Marion Roussel | Systemes transdermiques renfermant 2 principes actifs dans des compartiments separes, leur procede de preparation et leur application comme medicament |
| DE19814084B4 (de) * | 1998-03-30 | 2005-12-22 | Lts Lohmann Therapie-Systeme Ag | D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung |
| DE19938823A1 (de) * | 1999-08-19 | 2001-02-22 | Boehringer Ingelheim Pharma | Medikamentöse Behandlung des Restless Leg Syndroms |
| DE10041479A1 (de) * | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923 |
| ATE246919T1 (de) * | 2001-05-08 | 2003-08-15 | Sanol Arznei Schwarz Gmbh | Verbessertes transdermales therapeutisches system zur behandlung von morbus parkinson |
| EP1256339B1 (en) * | 2001-05-08 | 2003-10-15 | Schwarz Pharma Ag | Transdermal therapeutic system for Parkinson's disease inducing high plasma levels of rotigotine |
-
2002
- 2002-05-06 DE DE10220230A patent/DE10220230A1/de not_active Ceased
-
2003
- 2003-05-05 MX MXPA04010687A patent/MXPA04010687A/es active IP Right Grant
- 2003-05-05 UA UA20041109078A patent/UA81625C2/ru unknown
- 2003-05-05 JP JP2004500861A patent/JP5253707B2/ja not_active Expired - Lifetime
- 2003-05-05 KR KR10-2004-7017685A patent/KR20040104697A/ko not_active Ceased
- 2003-05-05 PL PL373276A patent/PL218549B1/pl unknown
- 2003-05-05 ES ES03727432T patent/ES2301795T3/es not_active Expired - Lifetime
- 2003-05-05 SI SI200331195T patent/SI1501499T1/sl unknown
- 2003-05-05 DK DK03727432T patent/DK1501499T3/da active
- 2003-05-05 AT AT03727432T patent/ATE387912T1/de active
- 2003-05-05 PT PT03727432T patent/PT1501499E/pt unknown
- 2003-05-05 CN CNB038160250A patent/CN100396281C/zh not_active Expired - Fee Related
- 2003-05-05 AU AU2003233233A patent/AU2003233233B2/en not_active Ceased
- 2003-05-05 IL IL16486103A patent/IL164861A0/xx unknown
- 2003-05-05 EP EP03727432A patent/EP1501499B1/de not_active Revoked
- 2003-05-05 WO PCT/EP2003/004685 patent/WO2003092677A1/de not_active Ceased
- 2003-05-05 RU RU2004131866/15A patent/RU2301063C9/ru active
- 2003-05-05 CA CA2483120A patent/CA2483120C/en not_active Expired - Fee Related
- 2003-05-05 DE DE50309318T patent/DE50309318D1/de not_active Expired - Lifetime
- 2003-05-05 CA CA2787384A patent/CA2787384A1/en not_active Abandoned
- 2003-05-05 NZ NZ536533A patent/NZ536533A/en not_active IP Right Cessation
- 2003-05-05 BR BR0309837-0A patent/BR0309837A/pt not_active Application Discontinuation
-
2004
- 2004-10-27 IL IL164861A patent/IL164861A/en active IP Right Grant
- 2004-11-02 ZA ZA2004/08862A patent/ZA200408862B/en unknown
- 2004-11-30 NO NO20045240A patent/NO333619B1/no not_active IP Right Cessation
-
2008
- 2008-05-02 CY CY20081100471T patent/CY1107452T1/el unknown
-
2010
- 2010-04-22 JP JP2010098924A patent/JP2010159302A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998031362A1 (en) * | 1997-01-17 | 1998-07-23 | Pharmacia & Upjohn Company | Use of pramipexole in the treatment of restless legs syndrome |
| DE19938825A1 (de) * | 1999-08-19 | 2001-04-26 | Boehringer Ingelheim Pharma | Wirkstoffkombination mit Clonidin |
Non-Patent Citations (1)
| Title |
|---|
| Clinical Pharmacology 24(3), 163-169 (2001) * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1501499B1 (de) | Transepikutane darreichungsform zur behandlung des restless leg syndroms | |
| DE19814084B4 (de) | D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung | |
| DE60100994T2 (de) | Transdermales therapeutisches System für die Erzielung hoher Plasmaspiegel von Rotigotin in der Therapie von Morbus Parkinson | |
| DE60100595T2 (de) | Verbessertes transdermales therapeutisches System zur Behandlung von Morbus Parkinson | |
| EP1490052B1 (de) | Vorrichtung zur transdermalen verabreichung von rotigotin-base | |
| DE69530004T2 (de) | Transdermale verabreichung von apomorphin | |
| DE69916492T3 (de) | Pflaster zur transdermalen applikation von flüchtigen, flüssigen wirkstoffen | |
| US20040048779A1 (en) | Use of rotigotine for treating the restless leg syndrome | |
| WO2005011687A1 (de) | Transdermales therapeutisches system mit dem wirkstoff pramipexol | |
| EP2111857A1 (de) | Transdermales therapeutisches System zur Verabreichung von Fentanyl oder einem Analogstoff hiervon | |
| EP2797588A1 (de) | Transdermales therapeutisches system mit geringer neigung zur spontankristallisation | |
| DE60309329T2 (de) | Verbessertes transdermales abgabesystem | |
| DE102006019293A1 (de) | Pflaster, enthaltend ein Fentanyl Analogum | |
| EP1171105A1 (de) | Transdermales therapeutisches system mit einem stark wirksamen neuroleptikum | |
| EP0659079B1 (de) | Transdermales therapeutisches system mit pentylentetrazol als wirkstoff | |
| EP3829550B1 (de) | Transdermales therapeutisches system zur abgabe von scopolamin ohne membran | |
| DE112009002721T5 (de) | Antiemetisches Pflaster | |
| CN117797125A (zh) | 含有秋水仙碱的贴剂及其制备方法和应用 | |
| DE10318714A1 (de) | Wirkstoff-Kombination und Therapien zur Bekämpfung des Alkoholmissbrauchs | |
| EP2079458A2 (de) | Transdermales therapeutisches system mit zweiphasigem freisetzungsprofil | |
| EP3854388A1 (de) | Transdermales therapeutisches system mit dem wirkstoff rotigotin und mindestens einem nicht aminresistenten silikonkleber | |
| DE10301930A1 (de) | Verfahren zur medikamentösen therapeutischen oder prophylaktischen Behandlung | |
| WO2008064815A2 (de) | Zubereitung zur transdermalen verabreichung von galanthamin | |
| HK1072541B (en) | Trans-epicutaneous administration form for treating restless leg syndrome | |
| DE102007008231A1 (de) | Pharmazeutische Zubereitung zur Behandlung der Migräne |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OP8 | Request for examination as to paragraph 44 patent law | ||
| 8131 | Rejection |